{"url_path":"/sec/mane/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1827635/0001827635-26-000019-index.html","accession_number":"0001827635-26-000019","cik":"0001827635","ticker":"MANE","issuer_name":"Veradermics, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1827635/0001827635-26-000019-index.html","primary_entity_key":"0001827635","primary_entity_name":"Veradermics, Inc"},"word_count":156,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nFrom January 1, 2026 to February 5, 2026 (the date of the filing of our registration statement on Form S-8, File No. 333-293238), we issued and sold to an employee an aggregate of 8,319 shares of Common Stock, before giving effect to the reverse stock split as part of our IPO, or 826 shares of Common Stock, after giving effect to the reverse stock split as part of our IPO, upon the exercise of stock options under our 2021 Stock Plan at an exercise price of $1.27 per share, for an aggregate purchase price of $10,565.13.\n\nUse of Proceeds\n\nOn January 30, 2026, the Company’s registration statement on Form S-1 (File No. 333-292657), or the IPO Prospectus, related to our IPO became effective.\n\nThere has been no material change in the planned use of proceeds from our IPO from that described in the IPO prospectus."}